Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
Identifieur interne : 002865 ( Main/Exploration ); précédent : 002864; suivant : 002866Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
Auteurs : Lewis J. Rubin [États-Unis] ; Nazzareno Galiè [Italie] ; Friedrich Grimminger ; Ekkehard Grünig [Allemagne] ; Marc Humbert [France] ; Zhi-Cheng Jing [République populaire de Chine] ; Anne Keogh [Australie] ; David Langleben [Canada] ; Arno Fritsch [Allemagne] ; Flavia Menezes [Brésil] ; Neil Davie [Allemagne] ; Hossein-Ardeschir Ghofrani [Royaume-Uni]Source :
- The European respiratory journal [ 1399-3003 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antagonistes des récepteurs de l'endothéline (usage thérapeutique), Antihypertenseurs (usage thérapeutique), Estimation de Kaplan-Meier, Facteurs temps, Femelle, Guanylate cyclase (métabolisme), Humains, Hypertension pulmonaire (traitement médicamenteux), Mâle, Méthode en double aveugle, Prostaglandines (), Pyrazoles (usage thérapeutique), Pyrimidines (usage thérapeutique), Qualité de vie, Résultat thérapeutique, Sujet âgé, Sécurité des patients, Épreuve d'effort, Études de suivi.
- MESH :
- métabolisme : Guanylate cyclase.
- traitement médicamenteux : Hypertension pulmonaire.
- usage thérapeutique : Antagonistes des récepteurs de l'endothéline, Antihypertenseurs, Pyrazoles, Pyrimidines.
- Adulte, Adulte d'âge moyen, Estimation de Kaplan-Meier, Facteurs temps, Femelle, Humains, Mâle, Méthode en double aveugle, Prostaglandines, Qualité de vie, Résultat thérapeutique, Sujet âgé, Sécurité des patients, Épreuve d'effort, Études de suivi.
English descriptors
- KwdEn :
- Adult, Aged, Antihypertensive Agents (therapeutic use), Double-Blind Method, Endothelin Receptor Antagonists (therapeutic use), Exercise Test, Female, Follow-Up Studies, Guanylate Cyclase (metabolism), Humans, Hypertension, Pulmonary (drug therapy), Kaplan-Meier Estimate, Male, Middle Aged, Patient Safety, Prostaglandins (chemistry), Pyrazoles (therapeutic use), Pyrimidines (therapeutic use), Quality of Life, Time Factors, Treatment Outcome.
- MESH :
- chemical , chemistry : Prostaglandins.
- chemical , metabolism : Guanylate Cyclase.
- chemical , therapeutic use : Antihypertensive Agents, Endothelin Receptor Antagonists, Pyrazoles, Pyrimidines.
- drug therapy : Hypertension, Pulmonary.
- Adult, Aged, Double-Blind Method, Exercise Test, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Patient Safety, Quality of Life, Time Factors, Treatment Outcome.
Abstract
Riociguat is a soluble, guanylate cyclase stimulator, approved for pulmonary arterial hypertension. In the 12-week PATENT-1 study, riociguat was well tolerated and improved several clinically relevant end-points in patients with pulmonary arterial hypertension who were treatment naïve or had been pretreated with endothelin-receptor antagonists or prostanoids. The PATENT-2 open-label extension evaluated the long-term safety and efficacy of riociguat. Eligible patients from the PATENT-1 study received riociguat individually adjusted up to a maximum dose of 2.5 mg three times daily. The primary objective was to assess the safety and tolerability of riociguat; exploratory efficacy assessments included 6-min walking distance and World Health Organization (WHO) functional class. Overall, 396 patients entered the PATENT-2 study and 324 (82%) were ongoing at this interim analysis (March 2013). The safety profile of riociguat in PATENT-2 was similar to that observed in PATENT-1, with cases of haemoptysis and pulmonary haemorrhage also being observed in PATENT-2. Improvements in the patients', 6-min walking distance and WHO functional class observed in PATENT-1 persisted for up to 1 year in PATENT-2. In the observed population at the 1-year time point, mean±sd 6-min walking distance had changed by 51±74 m and WHO functional class had improved in 33%, stabilised in 61% and worsened in 6% of the patients versus the PATENT-1 baseline. Long-term riociguat was well tolerated in patients with pulmonary arterial hypertension, and led to sustained improvements in exercise capacity and functional capacity for up to 1 year.
DOI: 10.1183/09031936.00090614
PubMed: 25614164
Affiliations:
- Allemagne, Australie, Brésil, Canada, France, Italie, Royaume-Uni, République populaire de Chine, États-Unis
- Angleterre, Bade-Wurtemberg, Californie, District de Karlsruhe, Grand Londres, Nouvelle-Galles du Sud, Québec, État de São Paulo, Île-de-France
- Heidelberg, Londres, Montréal, Orsay, Pékin, Sydney, São Paulo
- Université McGill, Université Paris-Sud
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002E14
- to stream PubMed, to step Curation: 002D38
- to stream PubMed, to step Checkpoint: 002D38
- to stream Ncbi, to step Merge: 002196
- to stream Ncbi, to step Curation: 002196
- to stream Ncbi, to step Checkpoint: 002196
- to stream Main, to step Merge: 002865
- to stream Main, to step Curation: 002865
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).</title><author><name sortKey="Rubin, Lewis J" sort="Rubin, Lewis J" uniqKey="Rubin L" first="Lewis J" last="Rubin">Lewis J. Rubin</name><affiliation wicri:level="2"><nlm:affiliation>Dept of Medicine, University of California, San Diego, La Jolla, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dept of Medicine, University of California, San Diego, La Jolla, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Galie, Nazzareno" sort="Galie, Nazzareno" uniqKey="Galie N" first="Nazzareno" last="Galiè">Nazzareno Galiè</name><affiliation wicri:level="1"><nlm:affiliation>Dept of Experimental, Diagnostic and Specialty Medicine-DIMES, Bologna University Hospital, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Dept of Experimental, Diagnostic and Specialty Medicine-DIMES, Bologna University Hospital, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Grimminger, Friedrich" sort="Grimminger, Friedrich" uniqKey="Grimminger F" first="Friedrich" last="Grimminger">Friedrich Grimminger</name><affiliation><nlm:affiliation>University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany Member of the German Center of Lung Research (DZL).</nlm:affiliation><wicri:noCountry code="subField">Germany Member of the German Center of Lung Research (DZL)</wicri:noCountry></affiliation></author><author><name sortKey="Grunig, Ekkehard" sort="Grunig, Ekkehard" uniqKey="Grunig E" first="Ekkehard" last="Grünig">Ekkehard Grünig</name><affiliation wicri:level="3"><nlm:affiliation>Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Humbert, Marc" sort="Humbert, Marc" uniqKey="Humbert M" first="Marc" last="Humbert">Marc Humbert</name><affiliation wicri:level="4"><nlm:affiliation>Université Paris-Sud, Le Kremlin-Bicêtre, France AP-HP Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France INSERM U999, LabEx LERMIT, Centre Chirurgical Marie Lannelongue, Le Plessis, Robinson, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Paris-Sud, Le Kremlin-Bicêtre, France AP-HP Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France INSERM U999, LabEx LERMIT, Centre Chirurgical Marie Lannelongue, Le Plessis, Robinson</wicri:regionArea><wicri:noRegion>Robinson</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Jing, Zhi Cheng" sort="Jing, Zhi Cheng" uniqKey="Jing Z" first="Zhi-Cheng" last="Jing">Zhi-Cheng Jing</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Keogh, Anne" sort="Keogh, Anne" uniqKey="Keogh A" first="Anne" last="Keogh">Anne Keogh</name><affiliation wicri:level="3"><nlm:affiliation>St Vincent's Hospital, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>St Vincent's Hospital, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Langleben, David" sort="Langleben, David" uniqKey="Langleben D" first="David" last="Langleben">David Langleben</name><affiliation wicri:level="4"><nlm:affiliation>Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region><settlement type="city">Montréal</settlement></placeName><orgName type="university">Université McGill</orgName></affiliation></author><author><name sortKey="Fritsch, Arno" sort="Fritsch, Arno" uniqKey="Fritsch A" first="Arno" last="Fritsch">Arno Fritsch</name><affiliation wicri:level="1"><nlm:affiliation>Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal</wicri:regionArea><wicri:noRegion>Wuppertal</wicri:noRegion><wicri:noRegion>Wuppertal</wicri:noRegion><wicri:noRegion>Wuppertal</wicri:noRegion></affiliation></author><author><name sortKey="Menezes, Flavia" sort="Menezes, Flavia" uniqKey="Menezes F" first="Flavia" last="Menezes">Flavia Menezes</name><affiliation wicri:level="3"><nlm:affiliation>Bayer HealthCare Pharmaceuticals, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Bayer HealthCare Pharmaceuticals, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Davie, Neil" sort="Davie, Neil" uniqKey="Davie N" first="Neil" last="Davie">Neil Davie</name><affiliation wicri:level="1"><nlm:affiliation>Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal</wicri:regionArea><wicri:noRegion>Wuppertal</wicri:noRegion><wicri:noRegion>Wuppertal</wicri:noRegion><wicri:noRegion>Wuppertal</wicri:noRegion></affiliation></author><author><name sortKey="Ghofrani, Hossein Ardeschir" sort="Ghofrani, Hossein Ardeschir" uniqKey="Ghofrani H" first="Hossein-Ardeschir" last="Ghofrani">Hossein-Ardeschir Ghofrani</name><affiliation wicri:level="3"><nlm:affiliation>University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany Member of the German Center of Lung Research (DZL) Dept of Medicine, Imperial College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany Member of the German Center of Lung Research (DZL) Dept of Medicine, Imperial College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25614164</idno><idno type="pmid">25614164</idno><idno type="doi">10.1183/09031936.00090614</idno><idno type="wicri:Area/PubMed/Corpus">002E14</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002E14</idno><idno type="wicri:Area/PubMed/Curation">002D38</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002D38</idno><idno type="wicri:Area/PubMed/Checkpoint">002D38</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002D38</idno><idno type="wicri:Area/Ncbi/Merge">002196</idno><idno type="wicri:Area/Ncbi/Curation">002196</idno><idno type="wicri:Area/Ncbi/Checkpoint">002196</idno><idno type="wicri:Area/Main/Merge">002865</idno><idno type="wicri:Area/Main/Curation">002865</idno><idno type="wicri:Area/Main/Exploration">002865</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).</title><author><name sortKey="Rubin, Lewis J" sort="Rubin, Lewis J" uniqKey="Rubin L" first="Lewis J" last="Rubin">Lewis J. Rubin</name><affiliation wicri:level="2"><nlm:affiliation>Dept of Medicine, University of California, San Diego, La Jolla, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dept of Medicine, University of California, San Diego, La Jolla, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Galie, Nazzareno" sort="Galie, Nazzareno" uniqKey="Galie N" first="Nazzareno" last="Galiè">Nazzareno Galiè</name><affiliation wicri:level="1"><nlm:affiliation>Dept of Experimental, Diagnostic and Specialty Medicine-DIMES, Bologna University Hospital, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Dept of Experimental, Diagnostic and Specialty Medicine-DIMES, Bologna University Hospital, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Grimminger, Friedrich" sort="Grimminger, Friedrich" uniqKey="Grimminger F" first="Friedrich" last="Grimminger">Friedrich Grimminger</name><affiliation><nlm:affiliation>University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany Member of the German Center of Lung Research (DZL).</nlm:affiliation><wicri:noCountry code="subField">Germany Member of the German Center of Lung Research (DZL)</wicri:noCountry></affiliation></author><author><name sortKey="Grunig, Ekkehard" sort="Grunig, Ekkehard" uniqKey="Grunig E" first="Ekkehard" last="Grünig">Ekkehard Grünig</name><affiliation wicri:level="3"><nlm:affiliation>Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Humbert, Marc" sort="Humbert, Marc" uniqKey="Humbert M" first="Marc" last="Humbert">Marc Humbert</name><affiliation wicri:level="4"><nlm:affiliation>Université Paris-Sud, Le Kremlin-Bicêtre, France AP-HP Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France INSERM U999, LabEx LERMIT, Centre Chirurgical Marie Lannelongue, Le Plessis, Robinson, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Paris-Sud, Le Kremlin-Bicêtre, France AP-HP Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France INSERM U999, LabEx LERMIT, Centre Chirurgical Marie Lannelongue, Le Plessis, Robinson</wicri:regionArea><wicri:noRegion>Robinson</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Jing, Zhi Cheng" sort="Jing, Zhi Cheng" uniqKey="Jing Z" first="Zhi-Cheng" last="Jing">Zhi-Cheng Jing</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Keogh, Anne" sort="Keogh, Anne" uniqKey="Keogh A" first="Anne" last="Keogh">Anne Keogh</name><affiliation wicri:level="3"><nlm:affiliation>St Vincent's Hospital, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>St Vincent's Hospital, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Langleben, David" sort="Langleben, David" uniqKey="Langleben D" first="David" last="Langleben">David Langleben</name><affiliation wicri:level="4"><nlm:affiliation>Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region><settlement type="city">Montréal</settlement></placeName><orgName type="university">Université McGill</orgName></affiliation></author><author><name sortKey="Fritsch, Arno" sort="Fritsch, Arno" uniqKey="Fritsch A" first="Arno" last="Fritsch">Arno Fritsch</name><affiliation wicri:level="1"><nlm:affiliation>Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal</wicri:regionArea><wicri:noRegion>Wuppertal</wicri:noRegion><wicri:noRegion>Wuppertal</wicri:noRegion><wicri:noRegion>Wuppertal</wicri:noRegion></affiliation></author><author><name sortKey="Menezes, Flavia" sort="Menezes, Flavia" uniqKey="Menezes F" first="Flavia" last="Menezes">Flavia Menezes</name><affiliation wicri:level="3"><nlm:affiliation>Bayer HealthCare Pharmaceuticals, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Bayer HealthCare Pharmaceuticals, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Davie, Neil" sort="Davie, Neil" uniqKey="Davie N" first="Neil" last="Davie">Neil Davie</name><affiliation wicri:level="1"><nlm:affiliation>Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal</wicri:regionArea><wicri:noRegion>Wuppertal</wicri:noRegion><wicri:noRegion>Wuppertal</wicri:noRegion><wicri:noRegion>Wuppertal</wicri:noRegion></affiliation></author><author><name sortKey="Ghofrani, Hossein Ardeschir" sort="Ghofrani, Hossein Ardeschir" uniqKey="Ghofrani H" first="Hossein-Ardeschir" last="Ghofrani">Hossein-Ardeschir Ghofrani</name><affiliation wicri:level="3"><nlm:affiliation>University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany Member of the German Center of Lung Research (DZL) Dept of Medicine, Imperial College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany Member of the German Center of Lung Research (DZL) Dept of Medicine, Imperial College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><series><title level="j">The European respiratory journal</title><idno type="eISSN">1399-3003</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antihypertensive Agents (therapeutic use)</term><term>Double-Blind Method</term><term>Endothelin Receptor Antagonists (therapeutic use)</term><term>Exercise Test</term><term>Female</term><term>Follow-Up Studies</term><term>Guanylate Cyclase (metabolism)</term><term>Humans</term><term>Hypertension, Pulmonary (drug therapy)</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Patient Safety</term><term>Prostaglandins (chemistry)</term><term>Pyrazoles (therapeutic use)</term><term>Pyrimidines (therapeutic use)</term><term>Quality of Life</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antagonistes des récepteurs de l'endothéline (usage thérapeutique)</term><term>Antihypertenseurs (usage thérapeutique)</term><term>Estimation de Kaplan-Meier</term><term>Facteurs temps</term><term>Femelle</term><term>Guanylate cyclase (métabolisme)</term><term>Humains</term><term>Hypertension pulmonaire (traitement médicamenteux)</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Prostaglandines ()</term><term>Pyrazoles (usage thérapeutique)</term><term>Pyrimidines (usage thérapeutique)</term><term>Qualité de vie</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sécurité des patients</term><term>Épreuve d'effort</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Prostaglandins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Guanylate Cyclase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antihypertensive Agents</term><term>Endothelin Receptor Antagonists</term><term>Pyrazoles</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypertension, Pulmonary</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Guanylate cyclase</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hypertension pulmonaire</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antagonistes des récepteurs de l'endothéline</term><term>Antihypertenseurs</term><term>Pyrazoles</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Double-Blind Method</term><term>Exercise Test</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Patient Safety</term><term>Quality of Life</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Estimation de Kaplan-Meier</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Prostaglandines</term><term>Qualité de vie</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sécurité des patients</term><term>Épreuve d'effort</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Riociguat is a soluble, guanylate cyclase stimulator, approved for pulmonary arterial hypertension. In the 12-week PATENT-1 study, riociguat was well tolerated and improved several clinically relevant end-points in patients with pulmonary arterial hypertension who were treatment naïve or had been pretreated with endothelin-receptor antagonists or prostanoids. The PATENT-2 open-label extension evaluated the long-term safety and efficacy of riociguat. Eligible patients from the PATENT-1 study received riociguat individually adjusted up to a maximum dose of 2.5 mg three times daily. The primary objective was to assess the safety and tolerability of riociguat; exploratory efficacy assessments included 6-min walking distance and World Health Organization (WHO) functional class. Overall, 396 patients entered the PATENT-2 study and 324 (82%) were ongoing at this interim analysis (March 2013). The safety profile of riociguat in PATENT-2 was similar to that observed in PATENT-1, with cases of haemoptysis and pulmonary haemorrhage also being observed in PATENT-2. Improvements in the patients', 6-min walking distance and WHO functional class observed in PATENT-1 persisted for up to 1 year in PATENT-2. In the observed population at the 1-year time point, mean±sd 6-min walking distance had changed by 51±74 m and WHO functional class had improved in 33%, stabilised in 61% and worsened in 6% of the patients versus the PATENT-1 baseline. Long-term riociguat was well tolerated in patients with pulmonary arterial hypertension, and led to sustained improvements in exercise capacity and functional capacity for up to 1 year.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Brésil</li><li>Canada</li><li>France</li><li>Italie</li><li>Royaume-Uni</li><li>République populaire de Chine</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Bade-Wurtemberg</li><li>Californie</li><li>District de Karlsruhe</li><li>Grand Londres</li><li>Nouvelle-Galles du Sud</li><li>Québec</li><li>État de São Paulo</li><li>Île-de-France</li></region><settlement><li>Heidelberg</li><li>Londres</li><li>Montréal</li><li>Orsay</li><li>Pékin</li><li>Sydney</li><li>São Paulo</li></settlement><orgName><li>Université McGill</li><li>Université Paris-Sud</li></orgName></list><tree><noCountry><name sortKey="Grimminger, Friedrich" sort="Grimminger, Friedrich" uniqKey="Grimminger F" first="Friedrich" last="Grimminger">Friedrich Grimminger</name></noCountry><country name="États-Unis"><region name="Californie"><name sortKey="Rubin, Lewis J" sort="Rubin, Lewis J" uniqKey="Rubin L" first="Lewis J" last="Rubin">Lewis J. Rubin</name></region></country><country name="Italie"><noRegion><name sortKey="Galie, Nazzareno" sort="Galie, Nazzareno" uniqKey="Galie N" first="Nazzareno" last="Galiè">Nazzareno Galiè</name></noRegion></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Grunig, Ekkehard" sort="Grunig, Ekkehard" uniqKey="Grunig E" first="Ekkehard" last="Grünig">Ekkehard Grünig</name></region><name sortKey="Davie, Neil" sort="Davie, Neil" uniqKey="Davie N" first="Neil" last="Davie">Neil Davie</name><name sortKey="Fritsch, Arno" sort="Fritsch, Arno" uniqKey="Fritsch A" first="Arno" last="Fritsch">Arno Fritsch</name></country><country name="France"><region name="Île-de-France"><name sortKey="Humbert, Marc" sort="Humbert, Marc" uniqKey="Humbert M" first="Marc" last="Humbert">Marc Humbert</name></region></country><country name="République populaire de Chine"><noRegion><name sortKey="Jing, Zhi Cheng" sort="Jing, Zhi Cheng" uniqKey="Jing Z" first="Zhi-Cheng" last="Jing">Zhi-Cheng Jing</name></noRegion></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Keogh, Anne" sort="Keogh, Anne" uniqKey="Keogh A" first="Anne" last="Keogh">Anne Keogh</name></region></country><country name="Canada"><region name="Québec"><name sortKey="Langleben, David" sort="Langleben, David" uniqKey="Langleben D" first="David" last="Langleben">David Langleben</name></region></country><country name="Brésil"><region name="État de São Paulo"><name sortKey="Menezes, Flavia" sort="Menezes, Flavia" uniqKey="Menezes F" first="Flavia" last="Menezes">Flavia Menezes</name></region></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Ghofrani, Hossein Ardeschir" sort="Ghofrani, Hossein Ardeschir" uniqKey="Ghofrani H" first="Hossein-Ardeschir" last="Ghofrani">Hossein-Ardeschir Ghofrani</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002865 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002865 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25614164
|texte= Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25614164" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |